ClinicalTrials.gg
CompletedNCT01733186Updated Jan 29, 2026Results posted

Evaluation of Safety and Exploratory Efficacy of CARTISTEM®, a Cell Therapy Product for Articular Cartilage Defects

A Phase 1/2 interventional study of CARTISTEM® in Degeneration Articular Cartilage Knee, sponsored by Medipost, Inc.. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-29.

Sponsored by Medipost, Inc. · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,029 studies in Osteoarthritis with a site in United States — 116 open to participants now, 175 under way, 14 of them phase 3. Osteoarthritis · United States.

Enrollment
768th of 832
12 · median 100
Started
2013
with 43 others
Phase 1/2
19 of 1,029
3 open now
Registered
419th of 1,029
by date

Among the 1,029 studies in Osteoarthritis with a site in United States, this one is the 768th largest by enrollment of the 832 interventional ones that give a count, is one of 44 that started in 2013, is one of 19 in phase 1/2, and was the 419th registered.

Osteoarthritis

2,977 studies on the registry are indexed under Osteoarthritis; 438 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

116 of the 1,029 studies in Osteoarthritis with a site in United States are open now. Recruiting first, the newest first:

111 more — sign in →

All 116 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 285 Osteoarthritis studies recruiting now, 158 (55%) set no upper age limit and 70 (25%) stop at 75 or younger; 22 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,029 studies in Osteoarthritis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether CARTISTEM, a cell therapeutic product, is safe and effective in the treatment of articular cartilage defects of the knee as a result of ageing, trauma, or degenerative diseases.

Read the detailed description

Conventional treatment modalities have not been able to provide complete and sustained resolution of symptoms following damage to the articular cartilage. Despite the numerous techniques available today, complete healing of damaged or defective cartilage or consistent reproduction of normal hyaline cartilage does not occur, and continuous drug administration or secondary surgeries are common.

Research in mesenchymal stem cells has had a rapid acceleration over the past decade and MSC-based therapy has become one of the objects of investigation for a new branch of medicine termed regenerative medicine. This emerging technology shows great promise for producing transplantable cartilage constructs to restore the function of degenerated joints.

CARTISTEM®, a combination of human umbilical cord blood-derived mesenchymal stem cells and sodium hyaluronate, is intended to be used as a single-dose cellular therapeutic agent for cartilage regeneration in human subjects with cartilage defects of the knee as a result of ageing, trauma, or degenerative diseases.

03

Conditions studied

  • Degeneration Articular Cartilage Knee

Browse trials for

Keywords

  • human umbilical cord blood-derived mesenchymal stem cells
  • MSC
  • cartilage lesion
  • cartilage defect
  • degenerative arthritis
  • stem cell implantation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with an intended- to- treat single focal, full-thickness cartilage defect (ICRS [International Cartilage Repair Society] Grade 3 or 4) of the knee as a result of ageing, trauma, or degenerative diseases.
  • Age ≥ 18 years old
  • Size of the articular cartilage lesion is ≥ 2 cm2
  • Swelling, tenderness and active range of motion ≤ Grade II
  • Joint pain : 20-mm - 60-mm on VAS (Visual Analog Scale) at the time of Screening
  • Appropriate blood coagulation, kidney and liver function laboratory parameters: PT() \< 1.5, APTT \<1.5×control Creatinine ≤ 2.0 mg/dL Albumin ≤ trace in urine dipstick test ≤ 2.0 mg/dL, /ALT ≤ 100 IU/L
  • Ligament instability ≤ Grade II
  • Lower extremity alignment within 5 degrees of the neutral weight bearing axis
  • No meniscal surgery within the past 3 months and more than 5mm of meniscal rim remaining
  • Ability and willingness to fully participate in the post-operative rehabilitation program
  • Subject is informed of the nature of this study, voluntarily agrees to participate in the study, and signs an IRBapproved prior to performing any of the screening procedures
  • (BMI) ≤ 35 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Patients who have been treated previously and are asymptomatic
  • Avascular necrosis/ osteonecrosis
  • or inflammatory joint disease
  • History of infection within the past 6 weeks
  • Surgery or radiation therapy within the past 6 weeks
  • Serious medical co-morbidities, which would otherwise contraindicate surgery, as determined by the investigator
  • Currently pregnant or nursing
  • Psychotic diseases, epilepsy, or any history of such diseases
  • Current abuse of alcohol (> 10 drinks weekly) and/or regular exposure to other substances of abuse, currently an active smoker
  • Chronic inflammatory articular diseases such as rheumatoid arthritis
  • Enrolled in any other clinical trials within the past 4 weeks
  • Administered such as Cyclosporin A or azathioprine within the past 6 weeks
  • Ligament instability > Grade II
  • Uncorrected significant lower extremity malalignment (i.e. > 5 degrees)
  • (sub-) Total meniscectomy (\<5mm rim remaining)
  • or viscosupplementation injection to the affected knee in the past 3 months
  • Principal investigator considers inappropriate for the clinical trial due to any reasons other than those listed above
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    CARTISTEM®

    Drug name and ingredients: CARTISTEM \[allogeneic-unrelated, umbilical cord blood-derived mesenchymal stem cells, ex vivo cultured, combined with sodium hyaluronate\] Dosage: Administer 0.5 mL of the combination product per cm\^2 of the cartilage defect

    Biological: CARTISTEM®

Interventions

  • BiologicalCARTISTEM®

    Also known as: human umbilical cord blood-derived mesenchymal stem cells

06

What researchers measure

Primary outcomes

  1. IKDC Score

    Subjects underwent a self-assessment of knee function using the IKDC (International Knee Documentation Committee Assessment)subjective knee evaluation before and after the administration of the IP. The assessment is designed to detect improvement or deterioration in symptoms, function, and sports activities due to knee impairment. The possible score ranges from 0 to 100, where 100 = no limitation with daily or sporting activities and the absence of symptoms. The IKDC assessment was performed before IP administration and at Months 12 after IP administration in an exploratory fashion. The IKDC score from the Month 12 visit was used as a primary indicator of the post operative change. The outcome was presented with the post-operative change amount from the baseline.

    Time frame: 12 months

Secondary outcomes

  1. VAS

    Subjects underwent a self-assessment of joint pain using the 100-mm VAS (Visual Analogue Scale) before and at Months 12 and 24 after IP (investigational product) administration. Higher values represent worse joint pain. Use of NSAIDs and any other analgesics had to be discontinued for 48 hours and 24 hours, respectively, prior to the 100 mm VAS evaluation. The outcome was presented with the post-operative change amount at Months 12 and 24 from the baseline. 100-mm VAS scores range from 0 to 100. Higher values represent worse joint pain.

    Time frame: 24 months

  2. Lysholm Score

    The Lysholm knee scoring scale is a self-assessment that rates the severity of common complaints related to knee problems, such as pain, swelling, abnormal sensations, and ability to squat or climb stairs. The possible score ranges from 0 to 100, where 100 = no symptoms or disability. Scores are categorized as excellent (95 to 100), good (84 to 94), fair (65 to 83), and poor (≤64). Subjects underwent a self-assessment of knee function using the Lysholm score before IP administration and at Months 12 and 24 after IP administration. The outcome was presented with the post-operative change amount at Months 12 and 24 from the baseline.

    Time frame: 24 months

  3. KOOS Score

    The Knee Injury and Osteoarthritis Outcome score (KOOS) knee survey is a self assessment of knee function and knee-related quality of life (QOL). Subjects responded to each question regarding knee-related symptoms, swelling, pain, impaired function, or changes in QOL with 1 of 5 possible answers that range from "never/not at all" to "always/extremely." The possible score for each parameter ranges from 0 to 100, where 0=extreme problems and 100=no problems. Subjects completed the KOOS knee survey before IP (investigational product) administration and at Month 24 after IP administration. The outcome was presented with the post-operative change amount at Month 24 from the baseline.

    Time frame: 24 months

  4. IKDC Score

    Subjects underwent a self-assessment of knee function using the IKDC subjective knee evaluation before and after the administration of the IP. The assessment is designed to detect improvement or deterioration in symptoms, function, and sports activities due to knee impairment. The possible score ranges from 0 to 100, where 100 = no limitation with daily or sporting activities and the absence of symptoms. The IKDC assessment was performed before IP administration and at Month 24 after IP administration in an exploratory fashion. The outcome was presented with the post-operative change amount at Month 24 from the baseline.

    Time frame: 24 months

07

Results

Posted Jul 30, 2021

Participant flow

Participant flow — Overall Study
MilestoneDose A CohortDose B Cohort
Started66
Completed66
Not completed00

Outcome measures

PrimaryIKDC Score

Subjects underwent a self-assessment of knee function using the IKDC (International Knee Documentation Committee Assessment)subjective knee evaluation before and after the administration of the IP. The assessment is designed to detect improvement or deterioration in symptoms, function, and sports activities due to knee impairment. The possible score ranges from 0 to 100, where 100 = no limitation with daily or sporting activities and the absence of symptoms. The IKDC assessment was performed before IP administration and at Months 12 after IP administration in an exploratory fashion. The IKDC score from the Month 12 visit was used as a primary indicator of the post operative change. The outcome was presented with the post-operative change amount from the baseline.

Time frame:
12 months
Reported as:
Mean · score on a scale
IKDC Score
score on a scaleDose A CohortDose B Cohort
IKDC Score32.0 ± 27.725.5 ± 18.9
SecondaryVAS

Subjects underwent a self-assessment of joint pain using the 100-mm VAS (Visual Analogue Scale) before and at Months 12 and 24 after IP (investigational product) administration. Higher values represent worse joint pain. Use of NSAIDs and any other analgesics had to be discontinued for 48 hours and 24 hours, respectively, prior to the 100 mm VAS evaluation. The outcome was presented with the post-operative change amount at Months 12 and 24 from the baseline. 100-mm VAS scores range from 0 to 100. Higher values represent worse joint pain.

Time frame:
24 months
Reported as:
Mean · score on a scale
VAS
score on a scaleDose A CohortDose B Cohort
12 MONTHS-23.8 ± 22.9-12.5 ± 31.5
24 MONTHS-31.7 ± 18.0-11.3 ± 30.2
SecondaryLysholm Score

The Lysholm knee scoring scale is a self-assessment that rates the severity of common complaints related to knee problems, such as pain, swelling, abnormal sensations, and ability to squat or climb stairs. The possible score ranges from 0 to 100, where 100 = no symptoms or disability. Scores are categorized as excellent (95 to 100), good (84 to 94), fair (65 to 83), and poor (≤64). Subjects underwent a self-assessment of knee function using the Lysholm score before IP administration and at Months 12 and 24 after IP administration. The outcome was presented with the post-operative change amount at Months 12 and 24 from the baseline.

Time frame:
24 months
Reported as:
Mean · score on a scale
Lysholm Score
score on a scaleDose A CohortDose B Cohort
12 MONTHS26.7 ± 20.522.5 ± 18.3
24 MONTHS32.0 ± 20.910.2 ± 13.0
SecondaryKOOS Score

The Knee Injury and Osteoarthritis Outcome score (KOOS) knee survey is a self assessment of knee function and knee-related quality of life (QOL). Subjects responded to each question regarding knee-related symptoms, swelling, pain, impaired function, or changes in QOL with 1 of 5 possible answers that range from "never/not at all" to "always/extremely." The possible score for each parameter ranges from 0 to 100, where 0=extreme problems and 100=no problems. Subjects completed the KOOS knee survey before IP (investigational product) administration and at Month 24 after IP administration. The outcome was presented with the post-operative change amount at Month 24 from the baseline.

Time frame:
24 months
Reported as:
Mean · score on a scale
KOOS Score
score on a scaleDose A CohortDose B Cohort
ADL (24 MONTHS)28.2 ± 25.712.3 ± 19.2
PAIN (24 MONTHS)23.6 ± 24.315.8 ± 13.1
QOL (24 MONTHS)50.0 ± 36.419.8 ± 24.2
SPORTS (24 MONTHS)39.2 ± 37.236.7 ± 31.9
SYMPTOM (24 MONTHS)24.4 ± 19.98.3 ± 12.3
SecondaryIKDC Score

Subjects underwent a self-assessment of knee function using the IKDC subjective knee evaluation before and after the administration of the IP. The assessment is designed to detect improvement or deterioration in symptoms, function, and sports activities due to knee impairment. The possible score ranges from 0 to 100, where 100 = no limitation with daily or sporting activities and the absence of symptoms. The IKDC assessment was performed before IP administration and at Month 24 after IP administration in an exploratory fashion. The outcome was presented with the post-operative change amount at Month 24 from the baseline.

Time frame:
24 months
Reported as:
Mean · score on a scale
IKDC Score
score on a scaleDose A CohortDose B Cohort
IKDC Score41.2 ± 25.827.5 ± 20.9

Adverse events

Collected over 24 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dose A Cohort0/6 (0%)0/6 (0%)6/6 (100%)
Dose B Cohort0/6 (0%)0/6 (0%)6/6 (100%)
Most frequent other events
Showing 10 of 21
Most frequent other events
EventDose A CohortDose B Cohort
JOINT RANGE OF MOTION DECREASEDMusculoskeletal and connective tissue disorders6/66/6
arthralgiaMusculoskeletal and connective tissue disorders5/66/6
muscle atrophyMusculoskeletal and connective tissue disorders5/61/6
joint effusionMusculoskeletal and connective tissue disorders3/63/6
joint swellingMusculoskeletal and connective tissue disorders3/63/6
prehypertensionVascular disorders3/60/6
bone marrow oedemaBlood and lymphatic system disorders1/62/6
joint crepitationMusculoskeletal and connective tissue disorders2/60/6
sinusitisInfections and infestations1/60/6
procedural painInjury, poisoning and procedural complications1/60/6

Baseline characteristics

Age, Continuous
Age, Continuous(years)Dose A CohortDose B CohortTotal
Mean36.3 ± 8.239.7 ± 8.038.0 ± 7.9
Sex: Female, Male
Sex: Female, Male(Participants)Dose A CohortDose B CohortTotal
Female112
Male5510
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Dose A CohortDose B CohortTotal
Hispanic or Latino000
Not Hispanic or Latino6612
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Dose A CohortDose B CohortTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American112
White5510
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Dose A CohortDose B CohortTotal
United States6612
Body mass index
Body mass index(kg/m^2)Dose A CohortDose B CohortTotal
Mean28.6 ± 4.126.6 ± 4.527.6 ± 4.3
08

Study locations

2 sites
  • Cartilage Restoration Center; RUSH University Medical Center
    Chicago, Illinois 60612, United States
  • Cartilage Repair Center; Brigham and Women's Hospital
    Chestnut Hill, Massachusetts 02467, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2013 to primary completion in Jun 2017, 52 months.

Results were first posted in Jul 2021, 4 years 1 month after primary completion. A results delay was requested in Aug 2018.

Of 25 phase 1/2 interventional studies under Osteoarthritis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's 52 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2012
First posted
Nov 26, 2012
StartActual
Jan 7, 2013
Primary completionActual
Jun 2, 2017
CompletionActual
Aug 29, 2017
Results delay requested
Aug 22, 2018
Results first posted
Jul 30, 2021
Last update
Jan 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01733186
Lead sponsor
Medipost, Inc.
Responsible party
Sponsor
First posted
Nov 26, 2012
Start date
Jan 7, 2013
Primary completion
Jun 2, 2017
Completion
Aug 29, 2017
Results posted
Jul 30, 2021
Last update
Jan 29, 2026

Study contacts

Brian J Cole, MD
principal investigator · Cartilage Restoration Center, Rush University Medical Center
Andreas H Gomoll, MD
principal investigator · Cartilage Repair Center, Brigham and Women's Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion